Business
Result of AGM and voting results
Result of AGM and voting results.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n26 June 2025\n \nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\nResult of AGM and voting results\nOndine Biomedical (AIM: OBI) announces that all resolutions set out in the Notice of AGM dated 4 June 2025 were duly passed at its Annual General Meeting (\"AGM\") held on 26 June 2025.\nThe voting results of the AGM were as follows:\n\n\n\n\n \n\n\nIn Favor\n\n\nAgainst\n\n\nWithheld\n\n\n\n\nResolution\n\n\nVotes\n\n\n%\n\n\nVotes\n\n\n%\n\n\nVotes\n\n\n%\n\n\n\n\n1. Election of Directors\n\n\n305,312,279\n\n\n100.00\n\n\n0\n\n\n0.00\n\n\n0\n\n\n0.00\n\n\n\n\nCarolyn Cross\n\n\n305,312,279\n\n\n100.00\n\n\n0\n\n\n0.00\n\n\n0\n\n\n0.00\n\n\n\n\nNicolas G. Loebel\n\n\n305,312,279\n\n\n100.00\n\n\n0\n\n\n0.00\n\n\n0\n\n\n0.00\n\n\n\n\nJean Charest\n\n\n305,312,279\n\n\n100.00\n\n\n0\n\n\n0.00\n\n\n0\n\n\n0.00\n\n\n\n\nJean Duvall\n\n\n302,712,279\n\n\n99.05\n\n\n0\n\n\n0.00\n\n\n2,900,000\n\n\n0.95\n\n\n\n\nJunaid Bajwa\n\n\n302,712,279\n\n\n99.05\n\n\n0\n\n\n0.00\n\n\n2,900,000\n\n\n0.95\n\n\n\n\nMargaret Shaw\n\n\n305,312,279\n\n\n100.00\n\n\n0\n\n\n0.00\n\n\n0\n\n\n0.00\n\n\n\n\n2. Appointment of Auditors\n\n\n305,312,279\n\n\n100.00\n\n\n0\n\n\n0.00\n\n\n0\n\n\n0.00\n\n\n\n\n \n \nEnquiries:\n\n\n\n\nOndine Biomedical Inc.\n\n\nwww.ondinebio.com\n\n\n\n\nCarolyn Cross, CEO \n\n\n+1 604 669 0555\nor via Vane Percy & Roberts\n\n\n\n\n \nStrand Hanson Limited (Nominated & Financial Adviser)\n\n\n \n\n\n\n\nJames Harris, Richard Johnson\n\n\n+44 (0)20 7409 3494\n\n\n\n\n \n\n\n \n\n\n\n\nRBC Capital Markets (Broker)\n\n\n \n\n\n\n\nKathryn Deegan\n\n\n+44 (0)20 7653 4000\n\n\n\n\n\n\n\n \n\n\n\n\nVane Percy & Roberts (Media Contact)\n\n\n\n\n\n\n\nSimon Vane Percy\n\n\n+44 (0)77 1000 5910\n\n\n\n\n \n \n \nAbout Ondine Biomedical Inc.\nOndine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.\nOndine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico ...